AMLX241220C4000
- 1.88
- +0.31+19.75%
Amylyx Pharmaceuticals Newsroom
Baird Upgrades Amylyx Pharmaceuticals(AMLX.US) to Buy Rating, Raises Target Price to $11
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Amylyx Pharmaceuticals Raised to Outperform From Neutral by Baird
Strong Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising Avexitide Prospects and Stable Financial Standing
Cautious Hold on Amylyx Pharmaceuticals Amid Uncertainty in Pipeline Progress
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript Summary
Amylyx Pharma Analyst Ratings
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $12
Express News | Amylyx Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $12 From $8
Q3 2024 Amylyx Pharmaceuticals Inc Earnings Call
Amylyx Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Express News | Amylyx Pharmaceuticals Inc: Cash Runway Expected Into 2026
Amylyx Pharmaceuticals | 8-K: Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
Express News | Amylyx Pharmaceuticals Q3 Operating Income USD -75.661 Million Vs. IBES Estimate USD -52.2 Million
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 81% Though Its Price And Business Still Lag The Industry
Earnings Preview: AMLX to Report Financial Results Pre-market on November 07
$Amylyx Pharmaceuticals(AMLX.US)$ is scheduled to release its financial results pre-market on November 07 ET. Earnings PreviewAnalysts estimate $Amylyx Pharmaceuticals(AMLX.US)$ to post revenue of
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
BofA Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating